BRPI0509331A - métodos para remover sódio e para remover sal de um indivìduo animal - Google Patents

métodos para remover sódio e para remover sal de um indivìduo animal

Info

Publication number
BRPI0509331A
BRPI0509331A BRPI0509331-7A BRPI0509331A BRPI0509331A BR PI0509331 A BRPI0509331 A BR PI0509331A BR PI0509331 A BRPI0509331 A BR PI0509331A BR PI0509331 A BRPI0509331 A BR PI0509331A
Authority
BR
Brazil
Prior art keywords
methods
sodium
animal
compositions
salt
Prior art date
Application number
BRPI0509331-7A
Other languages
English (en)
Inventor
Robert Alpern
Jerry M Buysse
Han Ting Chang
Dominique Charmot
Michael James Cope
John Fordtran
Gerrit Klaerner
Original Assignee
Ilypsa Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35054544&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0509331(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US10/814,527 external-priority patent/US7854924B2/en
Priority claimed from US10/813,872 external-priority patent/US8282960B2/en
Priority claimed from US10/814,749 external-priority patent/US8192758B2/en
Application filed by Ilypsa Inc filed Critical Ilypsa Inc
Publication of BRPI0509331A publication Critical patent/BRPI0509331A/pt
Publication of BRPI0509331B1 publication Critical patent/BRPI0509331B1/pt
Publication of BRPI0509331B8 publication Critical patent/BRPI0509331B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A61K31/78—Polymers containing oxygen of acrylic acid or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/795—Polymers containing sulfur
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/80—Polymers containing hetero atoms not provided for in groups A61K31/755 - A61K31/795
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/04—Chelating agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F120/00—Homopolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and only one being terminated by only one carboxyl radical or a salt, anhydride, ester, amide, imide or nitrile thereof
    • C08F120/02—Monocarboxylic acids having less than ten carbon atoms; Derivatives thereof
    • C08F120/04—Acids; Metal salts or ammonium salts thereof
    • C08F120/06—Acrylic acid; Methacrylic acid; Metal salts or ammonium salts thereof
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F128/00—Homopolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a bond to sulfur or by a heterocyclic ring containing sulfur
    • C08F128/02—Homopolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a bond to sulfur or by a heterocyclic ring containing sulfur by a bond to sulfur

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Polymers & Plastics (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"MéTODOS PARA REMOVER SóDIO E PARA REMOVER SAL DE UM INDIVìDUO ANIMAL". A presente invenção provê métodos e composições para o tratamento de desequilíbrios iónicos. Em particular, a invenção provê composições, que compreendem polímeros de ligação de sódio e composições farmacêuticas dos mesmos. Métodos de uso de composições poliméricas e farmacêuticas para benefícios terapêuticos e/ ou profiláticos são aqui expostos. Exemplos destes métodos incluem o tratamento de hipertensão, falha cardíaca crónica, doença renal em estágio terminal, cirrose hepática, insuficiência renal crónica.
BRPI0509331A 2004-03-30 2005-03-30 uso de uma composição de ligação de sódio BRPI0509331B8 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US10/814,527 US7854924B2 (en) 2004-03-30 2004-03-30 Methods and compositions for treatment of ion imbalances
US10/813,872 US8282960B2 (en) 2004-03-30 2004-03-30 Ion binding compositions
US10/814,749 US8192758B2 (en) 2004-03-30 2004-03-30 Ion binding compositions
US10/965,274 US7488495B2 (en) 2004-03-30 2004-10-13 Ion binding polymers and uses thereof
PCT/US2005/011010 WO2005094384A2 (en) 2004-03-30 2005-03-30 Methods and compositions for treatment of ion imbalances

Publications (3)

Publication Number Publication Date
BRPI0509331A true BRPI0509331A (pt) 2007-09-04
BRPI0509331B1 BRPI0509331B1 (pt) 2018-11-27
BRPI0509331B8 BRPI0509331B8 (pt) 2021-05-25

Family

ID=35054544

Family Applications (3)

Application Number Title Priority Date Filing Date
BRPI0509366A BRPI0509366B8 (pt) 2004-03-30 2005-03-30 composição farmacêutica, kit farmacêutico, e, uso de uma composição farmacêutica
BRPI0509365A BRPI0509365B8 (pt) 2004-03-30 2005-03-30 composição farmacêutica, kit farmacêutico, e, uso da referida composição
BRPI0509331A BRPI0509331B8 (pt) 2004-03-30 2005-03-30 uso de uma composição de ligação de sódio

Family Applications Before (2)

Application Number Title Priority Date Filing Date
BRPI0509366A BRPI0509366B8 (pt) 2004-03-30 2005-03-30 composição farmacêutica, kit farmacêutico, e, uso de uma composição farmacêutica
BRPI0509365A BRPI0509365B8 (pt) 2004-03-30 2005-03-30 composição farmacêutica, kit farmacêutico, e, uso da referida composição

Country Status (12)

Country Link
US (14) US7776319B2 (pt)
EP (3) EP1732516B1 (pt)
JP (3) JP4974882B2 (pt)
KR (3) KR101153035B1 (pt)
AU (3) AU2005228696B2 (pt)
BR (3) BRPI0509366B8 (pt)
CA (3) CA2557999C (pt)
DE (1) DE112005000730B4 (pt)
GB (3) GB2430624B (pt)
MX (1) MXPA06011270A (pt)
PL (1) PL1732523T3 (pt)
WO (3) WO2005094384A2 (pt)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2792363T3 (da) 2003-08-26 2016-09-26 Shire Biopharmaceuticals Holdings Ireland Ltd Farmaceutisk formulering, der omfatter lanthanforbindelser
US7381428B2 (en) 2003-08-26 2008-06-03 Shire International Licensing B.V. Stabilized lanthanum carbonate compositions
KR101153035B1 (ko) * 2004-03-30 2012-06-11 리립사, 인크. 이온 결합 조성물
DE602005019992D1 (de) * 2004-03-30 2010-04-29 Relypsa Inc Kaliumbindende polymere und ihre verwendungen
CN101321519A (zh) * 2005-09-30 2008-12-10 伊立普萨公司 制备含有交联壳的核-壳型复合物的方法及其得到的核-壳型复合物
WO2007038801A2 (en) * 2005-09-30 2007-04-05 Ilypsa, Inc. Monovalent cation-binding compositions comprising core-shell particles having crosslinked poly-vinylic shells, and methods of use thereof
JP2009510126A (ja) 2005-09-30 2009-03-12 レリプサ， インコーポレイテッド 哺乳類の胃腸管からカリウムイオンを選択的に除去するための方法および組成物
CN100398112C (zh) * 2006-03-24 2008-07-02 辽宁诺康生物制药有限责任公司 一种治疗血磷酸盐过多症的药物及其制备方法
PL2081551T3 (pl) * 2006-10-06 2013-06-28 Scil Tech Gmbh Wytworzenie wysuszonego rekonstytuowanego pęcherzyka do zastosowania farmaceutycznego
EP2107072A1 (en) * 2006-12-26 2009-10-07 Otsuka Pharmaceutical Factory, Inc. Sodium absorption inhibitor, potassium absorption inhibitor, phosphorus absorption inhibitor and preventive agent, therapeutic agent and food containing the same
EP2108661A1 (en) 2006-12-26 2009-10-14 Chisso Corporation Metal salt of crosslinked cellulose derivative
WO2008137318A1 (en) * 2007-05-04 2008-11-13 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating disorders associated with salt or fluid retention
JP2010538016A (ja) * 2007-08-29 2010-12-09 ソーベント セラピューティクス インコーポレイテッド 異なる対イオン含有量を有する吸収性ポリマー組成物、ならびにその調製および使用の方法
JP5294681B2 (ja) * 2008-04-28 2013-09-18 東京エレクトロン株式会社 基板処理装置及びその基板搬送方法
US20100111892A1 (en) * 2008-08-22 2010-05-06 Relypsa, Inc. Crosslinked polyfluoroacrylic acid and processes for the preparation thereof
WO2010022381A1 (en) * 2008-08-22 2010-02-25 Relypsa, Inc. Treating hyperkalemia with crosslinked cation exchange polymers of improved physical properties
WO2010022380A2 (en) * 2008-08-22 2010-02-25 Relypsa, Inc. Linear polyol stabilized polyfluoroacrylate compositions
EP4201408B1 (en) * 2008-08-22 2025-06-25 Vifor (International) Ltd. Crosslinked cation exchange polymers, compositions and use in treating hyperkalemia
AU2013204879B2 (en) * 2008-08-22 2015-10-29 Vifor (International) Ltd. Crosslinked cation exchange polymers, compositions and use in treating hyperkalemia
WO2010132662A1 (en) * 2009-05-13 2010-11-18 Relypsa, Inc. Powder formulations of potassium-binding active agents
TR201807469T4 (tr) 2010-03-20 2018-06-21 Relypsa Inc Polifloroakrilat partikülleri hazırlamaya yönelik kesintisiz işlem.
US9314523B2 (en) 2010-09-21 2016-04-19 Elwha Llc Ingestible salt grabber
CA2827056C (en) 2011-02-11 2020-07-14 Zs Pharma, Inc Microporous zirconium silicate for the treatment of hyperkalemia
CN110028603A (zh) 2011-06-27 2019-07-19 瑞立普萨公司 用于将聚合酯转化为聚合酸的方法
CN108276277A (zh) 2011-06-27 2018-07-13 瑞立普萨公司 丙烯酸酯及衍生物的氟化
US9943637B2 (en) 2012-06-11 2018-04-17 ZS Pharma, Inc. Microporous zirconium silicate and its method of production
MX2015000381A (es) * 2012-07-11 2015-11-23 Zs Pharma Inc Silicato de zirconio microporoso para el tratamiento de la hipercalemia en pacientes hipercalcemicos y composiciones con calcio mejoradas para el tratamiento de la hipercalemia.
IN2015DN01369A (pt) * 2012-07-19 2015-07-03 Relypsa Inc
EP2882798B1 (en) 2012-08-09 2019-05-08 Patheon Austria GmbH & Co KG Process for drying polymeric materials
ES3059226T3 (en) 2012-10-08 2026-03-19 Vifor Int Ltd Potassium-binding agents for treating hypertension and hyperkalemia
HRP20251373T1 (hr) 2012-10-22 2025-12-19 Zs Pharma, Inc Mikroporozni cirkonijev silikat za liječenje hiperkalijemije
US10695365B2 (en) 2012-10-22 2020-06-30 ZS Pharma, Inc. Microporous zirconium silicate for the treatment of hyperkalemia
KR102633597B1 (ko) 2013-06-05 2024-02-06 트리시다, 인크. 경구 투여를 위한 양성자-결합 중합체
US10393749B2 (en) * 2013-12-11 2019-08-27 Shiseido Company, Ltd. Marker for early diagnosis of kidney failure
US9675636B2 (en) * 2014-01-31 2017-06-13 University Of Kansas Micelle sequestering polymers
JP6468780B2 (ja) * 2014-09-30 2019-02-13 積水化成品工業株式会社 中空樹脂粒子及びその製造方法
IL322207A (en) 2014-12-10 2025-09-01 Tricida Inc Proton-binding polymers for oral administration
KR102674230B1 (ko) * 2014-12-23 2024-06-11 알데릭스, 인코포레이티드 고칼륨혈증의 치료를 위한 조성물 및 방법
US9592253B1 (en) 2015-10-14 2017-03-14 ZS Pharma, Inc. Extended use zirconium silicate compositions and methods of use thereof
ITUB20159278A1 (it) 2015-12-23 2017-06-23 Rjw Pharma Llc Procedimento per la sintesi di patiromer
IL262660B2 (en) 2016-05-06 2024-04-01 Tricida Inc Compositions for and method of treating acid-base disorders
JP2018125951A (ja) * 2017-01-31 2018-08-09 日本電産株式会社 モータ及びそれを備えた送風装置
IL319146A (en) 2017-11-03 2025-04-01 Tricida Inc Compositions for and method of treating acid-base disorders
JP7365631B2 (ja) * 2019-09-02 2023-10-20 国立大学法人福井大学 ホスホン酸又はホスホン酸エステル構造を有するコア－シェル型高分子微粒子、粒子分散液、成形体及び前記微粒子の製造方法
CN113244339B (zh) * 2021-06-04 2021-09-24 南京厚生药业有限公司 一种用于高脂血症的考来烯胺散及其制备方法
US20240139234A1 (en) * 2021-11-17 2024-05-02 Waterstone Pharmaceuticals (Wuhan) Co., Ltd. Pharmaceutical polymer for treating hyperkalemia and preparation method thereof
US20260043111A1 (en) * 2022-08-12 2026-02-12 University Of Kansas Extraction of critical minerals using polyanions

Family Cites Families (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2340111A (en) 1942-07-03 1944-01-25 Gen Electric Process for removing cations from liquid media
US2611730A (en) * 1950-09-02 1952-09-23 Simth Kline & French Lab Medical preparation for reducing the body level of sodium
US2798053A (en) * 1952-09-03 1957-07-02 Goodrich Co B F Carboxylic polymers
US2909462A (en) * 1955-12-08 1959-10-20 Bristol Myers Co Acrylic acid polymer laxative compositions
US3499960A (en) * 1965-01-25 1970-03-10 Merck & Co Inc Palatable coated particles of an anion exchange resin
FR2171934B1 (pt) 1972-02-16 1974-09-13 Rhone Poulenc Sa
US3974272A (en) * 1972-09-01 1976-08-10 Merck & Co., Inc. Palatable cholestyramine coacervate compositions
US4143130A (en) * 1977-08-29 1979-03-06 Warren-Teed Laboratories, Inc. Method for treating kidney stones
US4470975A (en) * 1977-10-21 1984-09-11 The Johns Hopkins University Method and composition for the elimination of water from an animal body
US4380590A (en) * 1978-09-19 1983-04-19 Rohm And Haas Company Emulsion copolymer cation exchange resins
US4191812A (en) * 1978-09-19 1980-03-04 Rohm And Haas Company Ion exchange process involving emulsion ion exchange resins
SE8003805L (sv) 1980-05-21 1981-11-22 Haessle Ab En farmaceutisk beredning med forbettrade utlosningsegenskap
US4362711A (en) 1980-07-11 1982-12-07 Evreka Inc. Blood cholesterol level reducing agent and method
DE3031737A1 (de) 1980-08-22 1982-04-01 Bayer Ag, 5090 Leverkusen Verfahren zur herstellung von perlpolymerisaten einheitlicher teilchengroesse
DE3149136A1 (de) 1981-12-11 1983-06-23 Robert Bosch Gmbh, 7000 Stuttgart Einrichtung zur regelung des kraftstoff-luftverhaeltnisses bei brennkraftmaschinen
JPS6090243A (ja) * 1983-10-25 1985-05-21 Nitto Boseki Co Ltd 小球状モノアリルアミン橋かけ重合体の製造方法
US5238924A (en) 1984-05-03 1993-08-24 Merck & Co., Inc. Treatment of renal diseases with ace inhibitors
KR920006865B1 (ko) 1984-05-18 1992-08-21 워싱톤 유니버시티 테크놀러지 어소우시에이츠 인코오퍼레이티드 입자나 액적을 피복하는 방법과 장치
US4747881A (en) * 1985-02-05 1988-05-31 Warner-Lambert Company Ingestible aggregate and delivery system prepared therefrom
US5186937A (en) * 1985-06-07 1993-02-16 A.E.C. Societe De Chimie Organique Et Biologique Composition for feeding ruminants
IT1190349B (it) * 1986-06-16 1988-02-16 Prodotti Formenti Srl Composizioni farmaceutiche ad attivita' sequestrante degli acidi biliari contenenti colestiramina quale principio attivo,e procedimento per prepararle
JPS63218713A (ja) 1987-02-17 1988-09-12 Daikin Ind Ltd α−フルオロアクリル酸系重合体ならびに用途
US4837015A (en) * 1987-03-05 1989-06-06 Carolina Medical Products Company, Inc. Alkali metal ion-charged, cation exchanger and use thereof to adjust sodium, potassium and calcium body fluid levels
US5210079A (en) 1988-01-07 1993-05-11 E. I. Du Pont De Nemours And Company Treatment of chronic renal failure with imidazole angiotensin-II receptor antagonists
FR2634377B1 (fr) * 1988-06-30 1991-09-27 Cortial Nouvelle forme pharmaceutique a liberation prolongee a base d'un complexe resine-principe actif
GB8817015D0 (en) * 1988-07-16 1988-08-17 Reckitt & Colmann Prod Ltd Method of treatment
GB8829088D0 (en) 1988-12-13 1989-01-25 Smith Kline French Lab Compounds
US5236701A (en) * 1989-07-19 1993-08-17 Lowchol Scientific Inc. Ingestible hydrophilic polymeric amines useful for lowering blood cholesterol
DE3928990A1 (de) 1989-09-01 1991-03-07 Bayer Ag Verfahren zur herstellung von (alpha)-fluoroacrylsaeurederivaten
US5112993A (en) 1989-11-14 1992-05-12 E. I. Du Pont De Nemours And Company Process for the preparation of difluoromaleic anhydride
US5091175A (en) * 1990-05-14 1992-02-25 Erbamont Inc. Pharmaceutical composition containing bile acid sequestrant enclosed in a size-exclusion membrane
DE69016014T2 (de) * 1990-07-04 1995-08-31 Marcin Krotkiewski Blutdrucksenkendes Präparat.
IE914179A1 (en) 1990-12-07 1992-06-17 Ici Plc Nitrogen derivatives
US5162110A (en) 1990-12-19 1992-11-10 Rhone-Poulenc Rorer Pharmaceuticals Inc. Binding theophylline to ion exchange resins
US5281631A (en) * 1991-12-20 1994-01-25 Arch Development Corp. Phosphonic acid based ion exchange resins
ATE130193T1 (de) * 1992-03-28 1995-12-15 Hoechst Ag Arzneimittel aus polyhydroxymethylenderivaten, verfahren zu deren herstellung und verwendung.
DK0656029T3 (da) * 1992-08-20 1999-02-15 Du Pont Tværbundne polymere ammoniumsalte
WO1994027619A1 (en) 1993-05-20 1994-12-08 Geltex Pharmaceuticals, Inc. Process for adjusting ion concentration in a patient and compositions therefor
US5487888A (en) * 1993-05-20 1996-01-30 Geltex, Inc. Iron-binding polymers for oral administration
US5607669A (en) 1994-06-10 1997-03-04 Geltex Pharmaceuticals, Inc. Amine polymer sequestrant and method of cholesterol depletion
US5618530A (en) * 1994-06-10 1997-04-08 Geltex Pharmaceuticals, Inc. Hydrophobic amine polymer sequestrant and method of cholesterol depletion
US5667775A (en) * 1993-08-11 1997-09-16 Geltex Pharmaceuticals, Inc. Phosphate-binding polymers for oral administration
WO1995014531A1 (en) 1993-11-25 1995-06-01 Salternate B.V. Particles for binding monovalent cations, use of such particles as well as methods for scavenging and removing sodium and/or potassium ions
TW474813B (en) * 1994-06-10 2002-02-01 Geltex Pharma Inc Alkylated composition for removing bile salts from a patient
US5846990A (en) 1995-07-24 1998-12-08 Bristol-Myers Squibb Co. Substituted biphenyl isoxazole sulfonamides
US5824339A (en) * 1995-09-08 1998-10-20 Takeda Chemical Industries, Ltd Effervescent composition and its production
US6498142B1 (en) * 1996-05-06 2002-12-24 Curis, Inc. Morphogen treatment for chronic renal failure
JP3885130B2 (ja) 1996-06-11 2007-02-21 株式会社大塚製薬工場 グアニジノ化合物低下剤並びに水分及びカリウムイオン吸着剤
PT1014941E (pt) 1996-06-26 2009-07-08 Univ Texas Formulação farmacêutica extrudível por termofusão
AU3649697A (en) 1996-06-27 1998-01-14 G.D. Searle & Co. Particles comprising amphiphilic copolymers, having a cross-linked shell domain and an interior core domain, useful for pharmaceutical and other applications
US6623759B2 (en) 1996-06-28 2003-09-23 Astrazeneca Ab Stable drug form for oral administration with benzimidazole derivatives as active ingredient and process for the preparation thereof
US5935599A (en) * 1996-10-28 1999-08-10 The Board Of Trustees Of The University Of Illinois Polymer-associated liposomes for drug delivery and method of manufacturing the same
JPH10130154A (ja) 1996-10-29 1998-05-19 Otsuka Pharmaceut Factory Inc 腎疾患患者用延命率改善薬
JP2001526212A (ja) 1997-12-19 2001-12-18 スミスクライン・ビーチャム・コーポレイション 咀嚼分散性錠剤の製造法
KR100440544B1 (ko) 1998-07-31 2004-07-15 니켄 가가쿠 가부시키가이샤 양이온 교환수지 제제
US6294163B1 (en) * 1998-10-02 2001-09-25 Geltex Pharmaceuticals, Inc. Polymers containing guanidinium groups as bile acid sequestrants
HUP0104249A3 (en) * 1998-11-06 2002-06-28 G D Searle & Co Chicago Pharmaceutical composition for combination therapy of angiotensin converting enzyme inhibitor and aldosterone antagonist for reducing morbidity and mortality from cardiovascular disease
CA2355829A1 (en) 1999-01-07 2000-07-13 Louise Templeton Multiparticulate oral dosage forms
US6558665B1 (en) * 1999-05-18 2003-05-06 Arch Development Corporation Encapsulating particles with coatings that conform to size and shape of the particles
US20020054903A1 (en) * 1999-10-19 2002-05-09 Joseph Tyler Direct compression polymer tablet core
US6733780B1 (en) * 1999-10-19 2004-05-11 Genzyme Corporation Direct compression polymer tablet core
US20030027789A1 (en) * 2000-01-14 2003-02-06 Ippei Yamaoka Inhibitors against sodium ion absorption, and preventive or therapeutic agents and foods containing the same
FR2812632B1 (fr) 2000-08-07 2003-03-07 Solvay Procede pour la synthese de composes fluoroorganiques
US6908609B2 (en) * 2000-11-20 2005-06-21 Dow Global Technologies Inc. In vivo use of water absorbent polymers
AU2002242103A1 (en) 2001-02-06 2002-08-19 Ash Medical Systems, Inc. Monovalent-selective cation exchangers as oral sorbent therapy
US7033639B2 (en) * 2001-05-16 2006-04-25 Rohm And Haas Company Polyaniline coating composition
US6881484B2 (en) * 2001-05-30 2005-04-19 Mitsubishi Kagaku Iatron, Inc. Core-shell particle including signal-generating substance enclosed therein and process for producing the same
JP2004149525A (ja) 2002-10-09 2004-05-27 Sekisui Chem Co Ltd カリウムイオン吸着剤及びその製造方法、並びに高カリウム血症治療剤
CA2516457C (en) 2003-02-25 2011-12-06 Finnfeeds Finland Oy A simulated moving bed system and process
CA2551528A1 (en) 2003-12-31 2005-07-21 Genzyme Corporation Enteric coated aliphatic amine polymer bile acid sequestrants
US7429394B2 (en) * 2004-03-30 2008-09-30 Relypsa, Inc. Ion binding compositions
US8192758B2 (en) 2004-03-30 2012-06-05 Relypsa, Inc. Ion binding compositions
US7556799B2 (en) 2004-03-30 2009-07-07 Relypsa, Inc. Ion binding polymers and uses thereof
KR101153035B1 (ko) 2004-03-30 2012-06-11 리립사, 인크. 이온 결합 조성물
US7854924B2 (en) 2004-03-30 2010-12-21 Relypsa, Inc. Methods and compositions for treatment of ion imbalances
US8282960B2 (en) 2004-03-30 2012-10-09 Relypsa, Inc. Ion binding compositions
JP2009510126A (ja) 2005-09-30 2009-03-12 レリプサ， インコーポレイテッド 哺乳類の胃腸管からカリウムイオンを選択的に除去するための方法および組成物
CN101321519A (zh) 2005-09-30 2008-12-10 伊立普萨公司 制备含有交联壳的核-壳型复合物的方法及其得到的核-壳型复合物
US20100111892A1 (en) 2008-08-22 2010-05-06 Relypsa, Inc. Crosslinked polyfluoroacrylic acid and processes for the preparation thereof
WO2010022381A1 (en) 2008-08-22 2010-02-25 Relypsa, Inc. Treating hyperkalemia with crosslinked cation exchange polymers of improved physical properties
WO2010022380A2 (en) 2008-08-22 2010-02-25 Relypsa, Inc. Linear polyol stabilized polyfluoroacrylate compositions

Also Published As

Publication number Publication date
JP2007531758A (ja) 2007-11-08
DE112005000730T5 (de) 2008-07-03
BRPI0509331B8 (pt) 2021-05-25
CA2558029A1 (en) 2005-10-20
JP2007531774A (ja) 2007-11-08
US20090148533A1 (en) 2009-06-11
US20130272992A1 (en) 2013-10-17
CA2557848A1 (en) 2005-10-20
GB2430368A (en) 2007-03-28
US20160317572A1 (en) 2016-11-03
US20130272991A1 (en) 2013-10-17
EP1732524A4 (en) 2007-09-19
CA2558029C (en) 2013-05-07
US8778324B2 (en) 2014-07-15
EP1732516B1 (en) 2009-12-30
CA2557999A1 (en) 2005-10-13
WO2005097081A1 (en) 2005-10-20
US20140286891A1 (en) 2014-09-25
BRPI0509366B1 (pt) 2018-07-24
US20110033505A1 (en) 2011-02-10
KR20060135045A (ko) 2006-12-28
BRPI0509365B1 (pt) 2018-06-12
US8475780B2 (en) 2013-07-02
GB2430367B (en) 2009-08-05
JP4964122B2 (ja) 2012-06-27
BRPI0509366A (pt) 2007-09-04
JP2007531726A (ja) 2007-11-08
AU2005231424B2 (en) 2010-06-17
EP1732523A1 (en) 2006-12-20
AU2005231424A1 (en) 2005-10-20
BRPI0509365B8 (pt) 2021-05-25
PL1732523T3 (pl) 2010-08-31
US8282913B2 (en) 2012-10-09
BRPI0509365A (pt) 2007-09-04
GB2430624B (en) 2009-08-05
US20160082039A1 (en) 2016-03-24
EP1732523B1 (en) 2010-03-17
EP1732523A4 (en) 2007-06-06
DE112005000730B4 (de) 2017-12-21
CA2557848C (en) 2013-12-10
US8216560B2 (en) 2012-07-10
GB0621241D0 (en) 2006-12-13
GB2430367A (en) 2007-03-28
EP1732523B9 (en) 2010-06-02
CA2557999C (en) 2013-11-12
US20060024265A1 (en) 2006-02-02
EP1732516A4 (en) 2007-06-06
MXPA06011270A (es) 2007-03-08
KR20060135044A (ko) 2006-12-28
WO2005094384A3 (en) 2006-01-26
JP5000480B2 (ja) 2012-08-15
JP4974882B2 (ja) 2012-07-11
KR101153035B1 (ko) 2012-06-11
BRPI0509366B8 (pt) 2021-05-25
US20080241092A1 (en) 2008-10-02
EP1732516A1 (en) 2006-12-20
AU2005231383A1 (en) 2005-10-20
BRPI0509331B1 (pt) 2018-11-27
GB0621242D0 (en) 2006-12-13
GB2430368B (en) 2009-08-26
US8287847B2 (en) 2012-10-16
US8445014B2 (en) 2013-05-21
US8889115B2 (en) 2014-11-18
AU2005228696B2 (en) 2010-06-24
GB0621244D0 (en) 2006-12-13
KR101228233B1 (ko) 2013-01-31
US20080241093A1 (en) 2008-10-02
EP1732524B1 (en) 2012-08-22
WO2005094384A2 (en) 2005-10-13
US7776319B2 (en) 2010-08-17
US10485821B2 (en) 2019-11-26
US20110206631A1 (en) 2011-08-25
US8409561B2 (en) 2013-04-02
GB2430624A (en) 2007-04-04
US20200085856A1 (en) 2020-03-19
AU2005228696A1 (en) 2005-10-13
KR20070007168A (ko) 2007-01-12
US20130272990A1 (en) 2013-10-17
AU2005231383B2 (en) 2010-06-10
WO2005097072A1 (en) 2005-10-20
EP1732524A2 (en) 2006-12-20
US20080233073A1 (en) 2008-09-25
KR101199608B1 (ko) 2012-11-08

Similar Documents

Publication Publication Date Title
BRPI0509331B8 (pt) uso de uma composição de ligação de sódio
EA201490822A1 (ru) Модифицированные полипептиды рецептора активина и их применение
WO2005092039A3 (en) Crosslinked amine polymers
CY1111388T1 (el) Συνδετικοι παραγοντες που αναστελλουν τη μυοστατινη
WO2002002638A3 (en) Methods for treating rheumatic diseases using a soluble ctla4 molecule
WO2005016266A3 (en) Methods for treating cardiovascular disease using a soluble ctla4 molecule
EA200501715A1 (ru) Замещённые аминокарбоновые кислоты в качестве ингибиторов протеинтирозинфосфатазы-1в
DE602004008762D1 (de) Substituierte heteroarylverbindungen als inhibitoren von proteintyrosinphosphatasen
WO2007038802A3 (en) Methods for preparing core-shell composites having cross-linked shells and core-shell composites resulting therefrom
ATE514714T1 (de) Hutnfr1-selektive antagonisten
EA200702656A1 (ru) Составы, содержащие пептиды, стимулирующие рецептор эритропоэтина, и их применение
WO2007045927A3 (en) Therapeutic agent
BRPI0307276B8 (pt) uso de um peptídio para prevenção e/ou tratamento de esclerose múltipla
DE60010192D1 (de) Tensidefreies Emulsionspolymerisationsverfahren
BRPI0415781A (pt) método para o tratamento de diabetes em um paciente e kit farmacêutico
DE602005020501D1 (de) Vernetzte aminpolymere
NL1027643A1 (nl) Werkwijze en systeem voor doelhoekhieleffectcompensatie.
EP1901659A4 (en) CONTRASTING AGENTS AND METHOD FOR PRODUCING CONTRASTING AGENTS
WO2006088958A8 (en) Encapsulated (chelate or ligand) dendritic polymers
DE602004010172D1 (de) Pharmazeutische zusammensetzungen zur behandlung von nierenfunktionsstörungen
ATE453383T1 (de) Ionenbindende zusammensetzungen
WO2008132732A3 (en) Methods and compositions for rectal administration of proteins
WO2004015390A3 (en) Lung cancer target proteins and use thereof
WO2004020457A3 (en) Methods and compositions for the inhibition of dna repair protein xrcc-3

Legal Events

Date Code Title Description
B25G Requested change of headquarter approved

Owner name: ILYPSA, INC. (US)

Free format text: ENDERECO ALTERADO CONFORME SOLICITADO NA PETICAO NO 020120015933/RJ DE 27/02/2012.

B25G Requested change of headquarter approved

Owner name: ILYPSA, INC. (US)

Free format text: ENDERECO ALTERADO CONFORME SOLICITADO NA PETICAO NO 020120016146/RJ DE 27/02/2012.

B25A Requested transfer of rights approved

Owner name: RELYPSA, INC. (US)

Free format text: TRANSFERIDO DE: ILYPSA, INC.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 27/11/2018, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 30/03/2005 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 18A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2716 DE 24-01-2023 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.